University of Texas Rio Grande Valley

ScholarWorks @ UTRGV
School of Medicine Publications and
Presentations

School of Medicine

12-2017

Transition from pre-diabetes to diabetes and predictors of risk in
Mexican-Americans
Shenghui Wu
Joseph B. Mccormick
University of Texas Health at Houston

Joanne E. Curran
The University of Texas Rio Grande Valley

Susan P. Fisher-Hoch
University of Texas Health at Houston

Follow this and additional works at: https://scholarworks.utrgv.edu/som_pub
Part of the Diseases Commons

Recommended Citation
Wu, S., McCormick, J. B., Curran, J. E., & Fisher-Hoch, S. P. (2017). Transition from pre-diabetes to
diabetes and predictors of risk in Mexican-Americans. Diabetes, Metabolic Syndrome and Obesity:
Targets and Therapy, 10, 491–503. https://doi.org/10.2147/DMSO.S136368

This Article is brought to you for free and open access by the School of Medicine at ScholarWorks @ UTRGV. It has
been accepted for inclusion in School of Medicine Publications and Presentations by an authorized administrator
of ScholarWorks @ UTRGV. For more information, please contact justin.white@utrgv.edu,
william.flores01@utrgv.edu.

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Dovepress

open access to scientific and medical research

ORIGINAL RESEARCH

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy downloaded from https://www.dovepress.com/ by 129.113.53.71 on 21-Jul-2020
For personal use only.

Open Access Full Text Article

Transition from pre-diabetes to diabetes and
predictors of risk in Mexican-Americans
This article was published in the following Dove Press journal:
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

Shenghui Wu 1
Joseph B McCormick 2
Joanne E Curran 3
Susan P Fisher-Hoch 2
1
Department of Epidemiology and
Biostatistics, University of Texas
Health at San Antonio-Laredo
Campus, Laredo, 2Division of
Epidemiology, University of Texas
Health Science Center-Houston,
School of Public Health, Brownsville
Campus, Brownsville, 3South Texas
Diabetes and Obesity Institute, School
of Medicine, University of Texas Rio
Grande Valley, Brownsville Campus,
Brownsville, TX, USA

Introduction

Correspondence: Shenghui Wu
University of Texas Health at San
Antonio, Department of Epidemiology
and Biostatistics, Laredo Campus,
Office# 2.100.32, 1937 E Bustamante St.,
Laredo, TX 78041, USA
Tel +1 956 523 7402
Fax +1 956 523 7411
Email wus@uthscsa.edu

The prevalence of type 2 diabetes has grown to epidemic proportions globally in
the last few decades.1,2 The burden is expected to increase even further due to aging,
urbanization and the increasing prevalence of physical inactivity and obesity.2 In the
USA, nearly 24 million persons have diabetes. One-quarter are undiagnosed and are
unaware of their condition. At least 57 million citizens have pre-diabetes, defined as
impaired fasting glucose of 100–125 mg/dL.3 By 2050, rates of diagnosed diabetes
are projected to reach 48 million.3 Globally, the International Diabetes Federation
estimates that there are currently 415 million people with diabetes, half of whom are
undiagnosed, and three-quarters live in low- and middle-income countries.4 Similarly,
the US burden is greatest in minorities such as Mexican-Americans.3
Impaired fasting glucose (100–125 mg/dL), impaired glucose tolerance (140–199
mg/dL at 2 hours) and/or impaired glycated hemoglobin (HbA1c, 5.7–6.4%) are
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Background: No studies have examined risk factors for the transition from pre-diabetes to
diabetes in populations with widespread obesity and diabetes. We determined proximal changes
and factors affecting the transition among Mexican-Americans with pre-diabetes.
Methods: Participants with pre-diabetes (n=285) were recruited from our randomly sampled
population-based Cameron County Hispanic Cohort. These participants were followed for an
average of 27 months with repeat examination every 3 to 4 months. Metabolic health was defined
as having less than 2 metabolic abnormalities (e.g., hypertension, elevated low-density lipoprotein, etc). Diabetes was identified as fasting blood glucose ≥126 mg/dL, glycated hemoglobin
≥6.5% and/or on hypoglycemic medication.
Results: Ninety-six of 285 (33.7%) participants transitioned to overt diabetes. The increased risk
of diabetes in the metabolically unhealthy varying with follow-up time was 81% (adjusted odds
ratio [OR]: 1.81; 95% CI: 1.09–3.02). The risk of diabetes increased 8% for each kg/m2 of increase
in body mass index (BMI, OR: 1.08; 95% CI: 1.05–1.11) independent of covariates. Transition to
diabetes was accompanied by a mean increase in BMI of 0.28 kg/m2, and deterioration in metabolic health of 9% (OR: 1.09; 95% CI: 1.003–1.18) compared with those who did not transition.
Conclusions: Deteriorating metabolic health and/or increasing BMI significantly raises the
risk of transitioning from pre-diabetes to diabetes. Transition itself was accompanied by further
increase in BMI and deterioration in metabolic health. These data underline the importance of
improving metabolic health and avoiding weight gain in pre-diabetes as simple but clear diabetes
prevention targets, and emphasize the importance of lifestyle management.
Keywords: transition, pre-diabetes, diabetes, predictors, risk, Mexican-Americans, Hispanic, Latino
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c lassified as pre-diabetes.5,6 The oral glucose tolerance test is
not widely used due to inconvenience, greater cost and lower
reproducibility than fasting blood glucose (FBG) or HbA1c,6
which are commonly used in clinics and in population-based
studies assessing the risk of diabetes. Several longitudinal
studies support the observation that pre-diabetes is a risk factor for diabetes, cardiovascular disease and even cancer,7–10
but no studies have examined risk factors for the transition
from pre-diabetes to diabetes and the proximal changes
accompanying this transition in populations with widespread
obesity and diabetes. The only relevant publication we are
aware of is a longitudinal study among American-Indians
without diabetes which showed that pre-diabetes at baseline
was an independent predictor of transition to type 2 diabetes,
compared to individuals with normal glucose metabolism
at baseline.11 That study found that measures of baseline
obesity, hemoglobin (HbA1c), FBG, 2-hour fasting plasma
glucose, fasting insulin, albuminuria and insulin resistance
helped predict transition.11 However, understanding proximal
events by characterizing established metabolic and other
markers accompanying transition to overt type 2 diabetes
should yield better understanding of the precipitating risk
factors among those with pre-diabetes.7–9 This would permit
distinguishing the person with pre-diabetes at risk of transition from those who are not. This study was to determine the
factors affecting transition from pre-diabetes to overt type 2
diabetes and proximal changes accompanying that transition
in a Mexican-American cohort with high prevalence rates
of diabetes (28%), obesity and undiagnosed pre-diabetes
(31.6%).12 Unique aspects of this intensive study are that
it provides longitudinal data, has general application and
particular relevance for the largest and most rapidly growing
minority in the USA.

Methods
Study participants
We created a nested cohort selected from our larger community-recruited and randomly sampled Cameron County
Hispanic Cohort (CCHC, n=3,627 at the time of this study;
currently 4,300), an on-going homogenous Mexican-American
cohort.13,14 From this cohort, we selected 285 adult participants
(Diabetes Risk Study [DRS] subjects) on the basis of prediabetes (FBG ≥100 mg/dL and <126 mg/dL and/or HbA1c
5.7%–6.4%) and examined them every 3 to 6 months for an
average of 27 months (range: 3–129 months). The participants
were randomly selected as part of the larger cohort, and we
selected 285 out of about 900 randomly selected participants
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(28% already had diabetes and another 32% had pre-diabetes).
So the 285 represented nearly all of those with pre-diabetes
in the early days of the cohort. The DRS started from April,
2004 and ended in December, 2015. This study was approved
by the Committee for the Protection of Human Subjects of the
University of Texas Health, Houston, TX, USA.

Admission DRS examinations
At enrollment to this nested cohort all DRS subjects provided
written informed consent. They then responded to a detailed
survey of sociodemographic characteristics, lifestyle including physical activity, diet, medical and family history, and
other potential exposures. Body measurements, including
current weight, height, and waist and hip circumferences
(HCs), were also taken.13,14 Weight was measured to the
nearest tenth of a kilogram and height to the nearest tenth
of a centimeter. Body mass index (BMI) was calculated by
dividing weight in kilograms by height squared in meters (kg/
m2). Waist circumference (WC) was measured at the level
of the umbilicus and HC at the level of maximum width of
buttocks with participants standing erect. Three blood pressure (BP) measurements were taken 5 minutes apart, and the
average of the second and third reading was used.
In line with standard CCHC protocols, all DRS subjects
provided blood sample at each visit following a 10 hours
overnight fast. After collection, samples were placed on ice
and centrifuged within 30 minutes. Following processing,
samples were frozen at −80°C. Laboratory studies included
complete blood count, metabolic and lipid panels, and HbA1c
at a Clinical Laboratory Improvement Amendments certified
laboratory. Fasting serum insulin was consistently performed
in-house using Mercodia immunoassays (Uppsala, Sweden).
Homeostasis model assessment insulin resistance (HOMAIR) index was calculated as (glucose [nmol/L]×insulin [µU/
mL]/22.5).15 High-sensitivity C-reactive protein (CRP) levels
were measured using Quantikine® ELISA kit (R&D Systems,
Inc., Minneapolis, MN, USA). The coefficient of variations
for all biomarkers ranged from 0.99% to 11%.

Intermediate follow-up examinations
(Short visit)
Every 3 to 4 months, a follow-up visit was performed, some
of which were in the home. Questionnaires were administered
to update demographic data, determine changes in diagnosed
conditions, doctor visits or hospitalization since the last visit.
Weight, WC, HC and BP were measured, and a blood sample
following a 10 hours overnight fast was stored at −80°C.
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Annual follow-up examinations
(Long visit)
Once a year, a complete clinical examination identical to the
admission protocol was performed in the clinic research unit.
Physical activity and dietary questionnaire were re-administered. The International Physical Activity Questionnaire
(IPAQ) short-form16 in the early years of the cohort or the
Godin Leisure-Time Exercise Questionnaire instruments 17 in
the later years of the cohort as reported previously18 was used
to re-access physical activity in a typical week according to
intensity, frequency (times/week) and duration (minutes/time).
Metabolic equivalent (MET) adjusted minutes of moderate
and vigorous physical activity in the last week were calculated
based on responses.19 Moderate and vigorous physical activity ≥600 MET adjusted minutes was considered meeting US
physical activity guidelines (USDHHS).19 Fruit and vegetable
consumption was assessed by asking subjects how many portions of fruit and vegetables they ate daily using the Food Frequency Questionnaire.20 A portion size was defined as a half
a cup of fresh, frozen or canned produce or a medium-sized
piece of produce.21,22 Eating ≥5 fruit and vegetable portions
daily was considered meeting US guidelines.21,22

Identification of diabetes
Diabetes was identified by the 2010 definition of diabetes of
the American Diabetes Association: an FBG ≥126 mg/dL or
HbA1c >6.5%6 or the subjects’ reporting being told by a health
care provider that they had diabetes or if they were taking
hypoglycemic medication. Transition to diabetes required two
fasting FBG measurements at least 1 day apart meeting the
American Diabetes Association criteria for diabetes.

Definition of metabolic health
Metabolic health was defined as having less than 2 of the
following metabolic abnormalities: systolic BP (SBP)
≥130 mmHg and/or diastolic BP (DBP) ≥85 mmHg or on
antihypertensive medication; triglyceride ≥150 mg/dL and
high-density lipoprotein-cholesterol (HDLC) <40 mg/dL
in men or <50 mg/dL in women.23,24 To avoid bias, we did
not use blood glucose levels nor diabetes medication in the
definition of metabolic health in our comparison of the risk
for diabetes in metabolically healthy and unhealthy groups.

Statistical analysis
Descriptive analyses were conducted to compare the characteristics of the DRS subjects who did or did not transition
to diabetes. Log-transformation was conducted to normalize
the distribution of continuous variables as appropriate. The

Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2017:10
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2-sample t-test was used to compare means for continuous
data. The Chi-square test was used to compare phenotypes
for categorical data. Incidence density (person-years per 100
individuals) was calculated to evaluate the transition rate
from pre-diabetes to diabetes, further classified by metabolic
health status at enrollment.
To explore the predictors reflecting the transition from
pre-diabetes to diabetes, the first overt diabetes transition was
treated as the outcome. Since the outcome measurements at
enrollment and the follow-up every 3–6 months are expected
to be correlated, Generalized Estimating Equations (GEE)
models were used to analyze the association between predicting factors and the risk of diabetes. Potential confounders
were adjusted for likely associated with diabetes outcomes.
Since our previous findings suggested the importance of
metabolic health on diabetes risk25 and the purpose being
to improve the power of statistics, our analyses used the
composite indicator – metabolic health rather than single
metabolic biomarker in the multivariable-adjusted models.
Besides age, gender and follow-up time, other factors with
significant univariate effect on diabetes risk were included
into the final model. To avoid bias, we did not examine the
association between diabetes risk and blood glucose levels,
HbA1c or HOMA-IR in the analyses since they were critical
components of the definition of diabetes. Potential confounders adjusted for in multivariable GEE models included age,
gender, follow-up time, and time-varying BMI, white blood
cell (WBC), insulin and metabolic health. Variables that were
not significant or not confounders were excluded from the
final model. The model including BMI did not include waistto-hip ratio (WHR)/WC at the same time due to its collinearity with BMI. The exposure by follow-up time interaction
term was also included into the model since it might suggest
that the exposure might vary as time progresses. GEE model
was also used to explore the predictors reflecting the transition from pre-diabetes to normal glucose level at the last visit.
The graph to present the cumulative incidence of diabetes over time was generated by a Cox regression model.
To illustrate the risk for diabetes over time, we also used a
restricted cubic spline GEE logistic regression analysis 26 to
evaluate the risk of diabetes with follow-up months. Knots
were placed at the 5th, 50th and 95th percentiles of the distribution of follow-up months.
Linear mixed-effects regression models with random
intercept were used to estimate the association between
repeated measures of markers such as plasma metabolic
biomarker concentrations as the outcome (dependent variable), and transition to diabetes as categorical exposure
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The mean age of 285 DRS subjects with pre-diabetes at
baseline was 50 years; 36% were male. During the average of
27 months of follow-up (range: 3–129 months), 96 (33.7%)
subjects transitioned from pre-diabetes to overt diabetes. The
overall incidence density was 12.4/100 person-years, but
14.7/100 person-years in metabolic unhealthy obese subjects
at enrollment and 6.4/100 person-years in metabolic healthy
normal weight subjects at enrollment. The overweight/obese
and metabolically unhealthy subjects have shorter time to
develop diabetes than the metabolic healthy normal weight
subjects (35.2 versus 31.4 months). Participants had 2–18
study visits (median 6 visits). The baseline BMI, WC, WHR
and the levels of fasting glucose, HbA1c, CRP and DBP were
significantly higher in subjects developing diabetes than those
without. For other characteristics, no significant differences
were observed between subjects developing diabetes and
those without. Detailed characteristics by diabetes status
during follow-up are shown in Table 1.
Table 2 presents the odds ratio (OR) of the transition
from pre-diabetes to diabetes over time, and the overall
associations between each marker and longitudinal overt
diabetes development during 129-month follow-up after the

pre-diabetes diagnosis. The risk of the transition from prediabetes to diabetes was not significantly associated with
follow-up time. However, WBC, insulin, HDLC, triglycerides, metabolic health, BMI, WC, WHR and SBP were all
significantly associated with the transition from pre-diabetes
to diabetes in the crude analysis (all Ps<0.05), but these associations were no longer significant for WBC, insulin, WHR
and SBP after adjusting for age, gender, follow-up time and
BMI or metabolic health. Other factors including physical
activity and diet were not statistically associated with the
risk of transition to diabetes. Since metabolic health included
HDLC, triglycerides and BP by definition, it was not put into
the multivariable-adjusted model together with its components at the same time. In the final multivariable-adjusted
GEE model (Table 3), only deteriorating metabolic health
and higher BMI were significantly associated with the risk
of transition to diabetes. The risk of diabetes increased 8%
when BMI increased 1 kg/m2 (OR: 1.08; 95% CI: 1.05–1.11)
excluding the effect of age, gender, metabolic health and
follow-up period. Compared with the metabolically healthy,
metabolically unhealthy DRS subjects increased their risk of
transition to diabetes by 81% (OR: 1.81; 95% CI: 1.09–3.02)
after adjusting for age, gender, BMI and follow-up time
(Table 3). Interaction terms were not statistically significant
in the final model. Table 4 shows the OR of the transition
from pre-diabetes to normal glucose level at the last visit over
time, and the significant influencing factors and longitudinal
normal glucose transition during 129-month follow-up after
the pre-diabetes diagnosis. The final model shows that insulin
increment significantly decreased the possibility to transition
from pre-diabetes to normal glucose level.
Figure 1 illustrates diabetes incidence increasing over
time after adjusting for age, gender, metabolic health and
time-varying BMI. Figure 2 visually depicts the shape of the
relationship between follow-up time and diabetes risk after
adjusting for potential confounding variables in a restricted
cubic spline model. Follow-up months were inversely associated with the risk of diabetes, although the association was
not significant (Ps for linear and nonlinear association >0.05).
Table 5 shows the changes of markers accompanying
transition from pre-diabetes to diabetes during the 129-month
follow-up after the diagnosis of pre-diabetes. Statistically
significant positive crude associations were found between
diabetes and both log-transformed insulin levels, BMI and
WC, but the association for insulin concentration became
non-significant after adjusting for follow-up time, age, gender, metabolic health and BMI (P=0.07). At any follow-up
time point, transition to diabetes in subjects increased BMI by
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(independent variable). Separate models were used for each
marker to examine the changes of each marker accompanying transition. The models also controlled for covariates
including follow-up months, time-varying BMI, time-varying
metabolic health, age and gender. Interaction terms between
diabetes and follow-up time were included to explore effect
modification of the rate of transition to diabetes. The GEE
model was used to analyze the effect of the transition from
pre-diabetes to diabetes (independent variable) on the categorical variable, metabolic health (dependent variable).
Potential confounders adjusted for in the multivariable GEE
model included age, gender, follow-up time and BMI. The
transition-to-diabetes by follow-up time interaction term was
also included into the model.
Linear mixed-effects regression models were used to
analyze the factors affecting the longitudinal change of fasting plasma glucose or HbA1c levels, respectively, after the
diagnosis of pre-diabetes. Besides age, gender and followup time, other factors with significant univariate effect on
glucose level or HbA1c levels were included into the final
models, respectively.
Statistical analyses were carried out by using SAS version
9.4 (SAS Institute, Cary, NC, USA). All statistical tests were
based on 2-sided probability.

Results
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Table 1 Cohort baseline characteristics according to the follow-up diabetes status: diabetes risk study (April, 2004–December, 2015)
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Characteristics
Categorical variables, n (%)
Gender
Men
Women
Employed
Yes
No
Ever cigarette smoking
Yes
No
Ever alcohol drinking
Yes
No
Education
Below high school
High school and above
Place of birth
Mexico
USA
Met minimum recommendations for physical activity of
≥600 MET-minutes/week
Yes
No
Met recommendations of ≥5 servings of fruit and vegetables per day
Yes
No
Continuous variables, Mean (SE)
Age at enrollment (years)
MET-minutes/week of moderate and vigorous activity (n=153)
Total portions of fruit and vegetables (n=150)
Anthropometrics
Body mass index (kg/m2)
Waist circumference (cm)
Waist-to-hip ratio
Metabolic markers
Insulin (mg/dL)a
Fasting plasma glucose (mg/dL)a
HOMA-IRa
HbA1c (%)
HbA1c (mmol/mol)
Total cholesterol (mg/dL)
Triglycerides (mg/dL)a
HDLC (mg/dL)
LDLC (mg/dL)
Blood pressure
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Metabolically unhealthyb
Yes
No
Inflammatory markersc
High-sensitivity CRP (mg/L)a,c
WBC count (103/μL)c

Overall

Developed diabetes during follow-up
Yes (n=96)

No (n=189)

P-value

102 (35.79)
183 (64.21)

28 (29.17)
68 (70.83)

74 (39.15)
115 (60.85)

0.10

161 (56.49)
120 (42.11)

50 (52.08)
44 (45.83)

111 (58.73)
76 (40.21)

0.48

39 (27.86)
101 (72.14)

8 (19.05)
34 (80.95)

31 (31.63)
67 (68.37)

0.13

67 (58.26)
48 (41.74)

24 (61.54)
15 (38.46)

43 (56.58)
33 (43.42)

0.61

160 (56.14)
125 (43.86)

60 (62.50)
36 (37.50)

100 (52.91)
89 (47.09)

0.12

202 (71.13)
82 (28.87)

70 (72.92)
26 (27.08)

132 (70.21)
56 (29.79)

0.63

41 (26.97)
111 (72.55)

8 (16)
42 (84)

33 (32.35)
69 (67.65)

0.03

40 (26.67)
110 (73.33)

14 (29.17)
34 (70.83)

26 (25.49)
76 (74.51)

0.64

50.24 (14.08)
1487 (4638)
3.68 (3.10)

52.06 (12.33)
876 (2471)
3.58 (2.62)

49.31 (14.04)
1783 (5371)
3.73 (3.32)

0.10
0.26
0.79

31.53 (5.79)
104.66 (13.02)
0.93 (0.06)

33.73 (6.00)
108.70 (12.54)
0.94 (0.06)

30.41 (5.36)
102.60 (12.79)
0.93 (0.06)

<.0001
0.0001
0.03

14.69 (1.87)
106.81 (1.06)
3.79 (1.89)
4.68 (0.81)
28 (8.9)
193.51 (38.10)
141.23 (1.58)
48.21 (12.19)
116.07 (34.53)

15.22 (1.55)
109.17 (1.06)
3.99 (1.56)
4.86 (0.82)
30 (9.0)
189.9 (36.34)
144.82 (1.63)
46.95 (10.50)
114.1 (36.19)

14.47 (2.01)
105.63 (1.05)
3.71 (2.03)
4.59 (0.78)
27 (8.5)
195.2 (38.93)
139.57 (1.56)
48.81 (12.91)
117.0 (33.81)

0.60
<.0001
0.45
0.01
0.01
0.37
0.61
0.33
0.58

119.21 (15.13)
73.99 (9.51)

121.5 (15.62)
75.89 (10.12)

118.0 (14.78)
73.03 (9.05)

0.07
0.02

59 (20.70)
226 (79.30)

21 (21.88)
75 (78.13)

38 (20.11)
151 (79.89)

0.73

3.71 (2.55)
6.42 (1.69)

4.65 (2.47)
6.59 (1.88)

3.33 (2.55)
6.33 (1.58)

0.03
0.25

Notes: aGeometric concentrations. bMetabolic health was defined as having less than 2 of the following metabolic abnormalities: systolic blood pressure ≥130 mmHg and/or
diastolic blood pressure ≥85 mmHg or on antihypertensive medication; triglyceride ≥150 mg/dL; HDLC <40 mg/dL in men or <50 mg/dL in women. cThe number for CRP is
58 in diabetes group and 120 in non-diabetes group; that for WBC is 86 and 172, respectively.
Abbreviations: CRP, C-reactive protein; HbA1c, glycated hemoglobin; HDLC, high-density lipoprotein-cholesterol; HOMA-IR, homeostasis model assessment insulin
resistance; LDLC, low-density lipoprotein-cholesterol; MET, metabolic equivalent; WBC, white blood cell.
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0.28 (SE: 0.13, P=0.04) kg/m2 and increased WC by 0.01 (SE:
0.004, P=0.004) cm as compared with subjects who did not
(the reference group), while controlling for other covariates.
Transition to diabetes was also associated with deterioration
in metabolic health by 9% (OR: 1.09; 95% CI: 1.003–1.18)
compared with those who did not transition. No statistically
significant associations were observed for other markers in
the crude and adjusted model.

Table 6 presents the factors affecting the longitudinal
change of fasting plasma glucose level after the pre-diabetes
diagnosis. Besides age, gender and follow-up time, other factors
with significant univariate effect on glucose level were included
in the final model. Older age, higher BMI and concentrations
of insulin, HbA1c and triglycerides significantly contribute to
the longitudinal increase in plasma fasting glucose concentrations after adjusting for follow-up time and gender. Similarly,

Table 2 OR and 95% CIs reflecting the transition from impaired fasting glucose to diabetes, and the overall associations between each
marker and longitudinal overt diabetes development during 129-month follow-up after the impaired fasting glucose diagnosisa
Effect

Crude analysis

Transition from impaired fasting glucose to overt diabetesc
Follow-up time (months) on diabetes risk
Inflammatory markers
CRP (mg/L)d
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
WBC count (103/μL)
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
Metabolic markers
Insulin (mg/dL)d
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
HDLC (mg/dL)e
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
Main effect×follow-up time on diabetes risk
LDLC (mg/dL)e
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
Main effect×follow-up time on diabetes risk
Total cholesterol (mg/dL)d
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
Triglycerides (mg/dL)d
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
Metabolic health statusd,f
Main effect of being metabolically unhealthy (yes versus
no) on diabetes risk
Follow-up time (months) on diabetes risk
Anthropometrics
BMI (kg/m2)d
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
Waist circumference (cm)
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
WHR
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk

Multivariable-adjusted analysisb

OR (95% CI)

P-value

OR (95% CI)

P-value

0.999 (0.99–1.01)

0.87

1.00 (0.99–1.01)

0.95

1.00 (0.99–1.02)
1.01 (0.997–1.03)

0.89
0.13

0.996 (0.98–1.01)
1.01 (0.997–1.03)

0.66
0.11

1.11 (1.01–1.22)
0.999 (0.99–1.01)

0.04
0.86

1.07 (0.96–1.20)
1.00 (0.99–1.01)

0.23
0.96

1.03 (1.01–1.05)
1.00 (1.02–1.02)

0.007
0.78

1.02 (0.99–1.05)
1.00 (0.99–1.01)

0.22
0.99

0.96 (0.92–0.998)
0.96 (0.92–1.005)
1.001 (1.00–1.002)

0.04
0.08
0.04

0.95 (0.91–0.99)
0.96 (0.93–0.999)
1.001 (1.0002–1.002)

0.02
0.046
0.02

1.01 (0.998–1.02)
1.06 (1.02–1.10)
0.9995 (0.999–0.9999)

0.09
0.003
0.005

1.01 (0.999–1.02)
1.06 (1.01–1.10)
0.9996 (0.999–0.9999)

0.09
0.008
0.01

1.00 (0.99–1.01)
1.01 (0.996–1.02)

0.97
0.18

1.00 (0.99–1.01)
1.01 (0.996–1.02)

0.86
0.20

1.00 (1.00–1.01)
1.01 (0.997–1.02)

0.046
0.14

1.005 (1.001–1.01)
1.01 (0.997–1.02)

0.01
0.14

2.03 (1.23–3.36)

0.006

1.81 (1.09–3.02)

0.02

0.999 (0.99–1.01)

0.80

0.9997 (0.99–1.01)

0.96

1.09 (1.06–1.11)
1.00 (0.99–1.01)

<0.0001
0.89

1.09 (1.06–1.12)
1.00 (0.99–1.01)

<0.0001
0.95

1.04 (1.03–1.05)
1.00 (0.99–1.01)

<0.0001
0.94

1.03 (1.0001–1.06)
1.00 (0.99–1.01)

0.046
0.92

1.04 (1.01–1.08)
0.999 (0.99–1.01)

0.009
0.85

1.05 (0.996–1.11)
0.998 (0.86–1.16)

0.08
0.98
(Continued)
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Table 2 (Continued)
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Crude analysis
Blood pressure
Systolic blood pressure (mmHg)d
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
Diastolic blood pressure (mmHg)d
Main effect of the marker on diabetes risk
Follow-up time (months) on diabetes risk
Met minimum recommendations for physical activity
of ≥600 MET-minutes/week
Main effect of physical activity on diabetes risk
Follow-up time (months) on diabetes risk
Met recommendations of ≥5 servings of fruit and
vegetables per day
Main effect of fruit and vegetables intake on diabetes
risk
Follow-up time (months) on diabetes risk

Multivariable-adjusted analysisb

OR (95% CI)

P-value

OR (95% CI)

P-value

1.01 (1.003–1.02)
0.999 (0.99–1.01)

0.01
0.88

1.01 (0.999–1.02)
1.001 (0.99–1.01)

0.08
0.93

1.01 (0.99–1.03)
0.999 (0.989–1.01)

0.23
0.89

1.01 (0.99–1.03)
1.00 (0.99–1.01)

0.24
0.96

1.25 (0.61–2.56)
1.008 (0.99–1.02)

0.55
0.23

1.36 (0.63–2.95)
1.007 (0.99–1.02)

0.43
0.30

0.95 (0.37–2.46)

0.92

0.98 (0.38–2.52)

0.96

1.008 (0.99–1.02)

0.25

1.007 (0.99–1.02)

0.29

Notes: aSeparate Generalized Estimating Equations models were used to test the transition from impaired fasting glucose to overt diabetes and the association between each
marker (independent variable) and diabetes (dependent variable) over time. P<0.05 for the diabetes risk changes over time of the study for any marker. The estimate for the
main effect of the marker represents the change in the OR of diabetes occurrence corresponding to a 1-unit increase in a marker at any follow-up time while holding all other
predictors fixed. The estimate for the effect of metabolic health represents the change in the OR of diabetes occurrence corresponding to being metabolically unhealthy
versus being metabolically healthy at any follow-up time, controlling for other predictors. The estimate for follow-up time on diabetes risk represents if there is a decline/
increase over time in the risk of diabetes when all other predictors are fixed. The estimate for the main effect×follow-up time interaction represents effect modification of
the diabetes status change by a marker; the change in diabetes status in the marker over each month of follow-up time, holding other predictors constant. bAdjusted for
age, gender and time-varying BMI. cAn average of 9 repeated measures at every 3 to 6 months for an average of 27 months (range: 3–129 months) since baseline. dP>0.05 for
the interactions between time and markers and the model did not include the interaction term due to P>0.05. eFurther adjusted for the interaction term between time and
markers. fMetabolic health was defined as having less than 2 of the following metabolic abnormalities: systolic blood pressure ≥130 mmHg and/or diastolic blood pressure
≥85 mmHg or on antihypertensive medication; triglyceride ≥150 mg/dL; high-density lipoprotein cholesterol <40 mg/dL in men or <50 mg/dL in women.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; HDLC, high-density lipoprotein-cholesterol; LDLC, low-density lipoprotein-cholesterol; MET, metabolic
equivalent; OR, odds ratio; WBC, white blood cell; WHR, waist-to-hip ratio.

Table 3 Multivariable-adjusted OR and 95% CIs reflecting the
transition from impaired fasting glucose to diabetes, and the association
between factors and longitudinal overt diabetes development during
129-month follow-up after the impaired fasting glucose diagnosisa
Factors

Follow-up time (months)
Age (years)
Gender (women versus men)
BMI (kg/m2)
Metabolically unhealthy (yes versus no)c

Multivariableadjusted analysisb
OR (95% CI)

P-value

1.00 (0.99–1.01)
1.01 (0.996–1.02)
1.10 (0.73–1.67)
1.08 (1.05–1.11)
1.81 (1.09–3.02)

0.96
0.17
0.65
<0.0001
0.02

Notes: aThe Generalized Estimating Equations model was used to test the transition
from impaired fasting glucose to overt diabetes and the association between multiple
factors and diabetes over time. The estimate for the effect of the factor (continuous
variable) represents the change in the OR of diabetes occurrence corresponding to
a 1-unit increase in a factor at any follow-up time while holding all other predictors
fixed. bThe estimate for the effect of metabolic health represents the change in
the OR of diabetes occurrence corresponding to being metabolically unhealthy
compared with being metabolically healthy at any follow-up time, controlling for
other predictors. The estimate for follow-up time on diabetes risk represents if
there is a decline/increase over time in the risk of diabetes when all other predictors
are fixed. The effect of the factor×follow-up time interaction terms was not
significant in models. cAdjusted for age, gender, time-varying BMI, metabolic health.
Waist-to-hip ratio was not adjusted for in this model due to its collinearity with
BMI; homeostasis model assessment insulin resistance was not included in the model
due to its calculation based on glucose and insulin. Metabolic health was defined as
having less than 2 of the following metabolic abnormalities: systolic blood pressure
≥130 mmHg and/or diastolic blood pressure ≥85 mmHg or on antihypertensive
medication; triglyceride ≥150 mg/dL; high-density lipoprotein cholesterol <40 mg/dL
in men or <50 mg/dL in women.
Abbreviations: BMI, body mass index; OR, odds ratio.
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Table 4 Multivariable-adjusted OR and 95% CIs reflecting the
transition from impaired fasting glucose to normal level, and
the association between factors and longitudinal reverting to
normal blood glucose level during 129-month follow-up after the
impaired fasting glucose diagnosisa
Model*

Multivariableadjusted analysisb
OR (95% CI)

P-value

Follow-up time (months)
Age (years)
Gender (women versus men)
Insulin (mg/dL)

1.04 (1.02–1.05)
0.99 (0.96–1.01)
2.05 (0.97–4.33)
0.49 (0.31–0.78)

<0.0001
0.37
0.06
0.003

Notes: aEighty-two subjects were reverting to normal level at the last visit from
impaired fasting glucose since enrollment. The Generalized Estimating Equations
model was used to test the transition from impaired fasting glucose to overt diabetes
and the association between multiple factors and diabetes over time. The estimate
for the effect of the factor (continuous variable) represents the change in the OR of
diabetes occurrence corresponding to a 1-unit increase in a factor at any follow-up
time while holding all other predictors fixed. The estimate for the effect of metabolic
health represents the change in the OR of diabetes occurrence corresponding to
being metabolically unhealthy compared with being metabolically healthy at any
follow-up time, controlling for other predictors. The estimate for follow-up time
on diabetes risk represents if there is a decline/increase over time in the risk of
diabetes when all other predictors are fixed. The effect of the factor×follow-up time
interaction terms was not significant in models. bThe final multivariable-adjusted
models included significant variables except for age, gender and follow-up period.
*The final multivariable-adjusted models only included significant variables except
for age, gender and follow-up period.
Abbreviation: OR, odds ratio.
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Figure 1 The cumulative incidence of diabetes rate by follow-up time.
Note: The model was adjusted for age, sex, metabolic health and time-varying body mass index.
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Figure 2 Smoothed plot for ORs of the diabetes risk according to follow-up time.
Notes: The ORs were estimated by using the restricted cubic-spline Generalized Estimating Equations logistic models with knots placed at the 5th, 50th, and 95th percentiles
of follow-up months. The linear regression was not significant (P=0.82), and the nonlinear regression was not significant (P=0.76). The model was adjusted for age, sex,
metabolic health and time-varying body mass index.
Abbreviation: ORs, odds ratios.
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Table 5 The changes of markers accompanying transition from impaired fasting glucose to overt type 2 diabetes during 129-month
follow-up after the diagnosis of impaired fasting glucosea
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy downloaded from https://www.dovepress.com/ by 129.113.53.71 on 21-Jul-2020
For personal use only.

Variables
Continuous variables
Inflammatory markers
CRP (mg/L)c,d
Main effect of transition on CRP
Follow-up time (months) effect on CRP
WBC count (103/μL)c,d
Main effect of transition on WBC
Follow-up time (months) effect on WBC
Metabolic markers
Insulin (mg/dL)c,d
Main effect of transition on insulin
Follow-up time (months) effect on insulin
HDLC (mg/dL)c,d
Main effect of transition on HDLC
Follow-up time (months) effect on HDLC
LDLC (mg/dL)c,d
Main effect of transition on LDLC
Follow-up time (months) effect on LDLC
TC (mg/dL)c,d
Main effect of transition on TC
Follow-up time (months) effect on TC
TG (mg/dL)c,d
Main effect of transition on TG
Follow-up time (months) effect on TG
Anthropometrics
BMI (kg/m2)d
Main effect of transition on BMI
Follow-up time (months) effect on BMI
WC (cm)
Main effect of transition on WC
Follow-up time (months) effect on WC
WHRd
Main effect of transition on WHR
Follow-up time (months) effect on WHR
Blood pressure
SBP (mmHg)c,d
Main effect of transition on SBP
Follow-up time (months) effect on SBP
DBP (mmHg)c,d
Main effect of transition on DBP
Follow-up time (months) effect on DBP
Categorical variables
Metabolically unhealthy (yes versus no)f
Main effect of transition on metabolically unhealthy
Follow-up time (months) effect on metabolically unhealthy

Crude analysis

Multivariable-adjusted analysisb

Estimate (SE)

P-value

Estimate (SE)

P-value

0.11 (0.20)
0.01 (0.002)

0.57
<0.0001

–0.006 (0.19)
0.01 (0.002)

0.97
<0.0001

0.004 (0.02)
−0.0005 (0.0002)

0.84
0.04

−0.001 (0.02)
−0.0005 (0.0003)

0.97
0.18

0.18 (0.08)
−0.003 (0.0008)

0.02
<0.0001

0.13 (0.07)
−0.002 (0.0008)

0.09
0.003

0.02 (0.03)
−0.0009 (0.0003)

0.57
0.001

0.02 (0.03)
−0.001 (0.0003)

0.60
<0.0001

–0.01 (0.04)
–0.001 (0.0004)

0.75
0.007

−0.01 (0.04)
−0.001 (0.0004)

0.81
0.006

0.009 (0.02)
−0.0009 (0.0002)

0.68
<0.0001

0.007 (0.02)
−0.001 (0.0002)

0.75
<0.0001

0.02 (0.05)
−0.0004 (0.0005)

0.68
0.43

0.02 (0.05)
−0.0003 (0.0005)

0.74
0.49

0.34 (0.14)
0.002 (0.002)

0.02
0.26

0.28 (0.13)
0.01 (0.002)

0.04
<0.0001

0.02 (0.005)
0.00,007 (0.00006)

0.0001
0.17

0.01 (0.004)
−0.0001 (0.00005)

0.004
0.02

0.007 (0.004)
0.0003 (0.00,005)

0.07
<0.0001

0.008 (0.004)
0.0002 (0.00,005)

0.054
0.003

−0.002 (0.009)
−0.00004 (0.0001)

0.86
0.71

−0.003 (0.009)
−0.0003 (0.0001)

0.78
0.007

−0.01 (0.01)
−0.0002 (0.0001)
Crude analysis

0.35
0.15

0.27
−0.01 (0.01)
0.40
−0.0001 (0.0001)
Multivariable-adjusted analysise

OR (95% CI)

P-value

OR (95% CI)

P-value

1.10 (1.02–1.20)
0.999 (0.998–0.9999)

0.02
0.03

1.09 (1.003–1.18)
0.999 (0.998–0.9999)

0.04
0.03

Notes: aSeparate linear mixed-effects models were used to test the associations between diabetes development (independent variable) and each marker (dependent variable)
for an average of 9 repeated measures at every 3 to 6 months for an average of 27 months (range: 3–129 months) since baseline. The estimate for the main effect represents
the difference in a marker with diabetes occurrence at any follow-up time, controlling for other predictors. The estimate for follow-up time represents the rate of a marker
change; the difference in the marker per month of follow-up when all other predictors are fixed. For example, an estimate of 0.10 for the main effect represents an increase
of 0.10 in a marker with diabetes occurrence at any follow-up time, controlling for other predictors. An estimate of 0.01 for follow-up time represents the increasing rate
of 0.01 of a marker change; the increase of 0.01 in the marker per month of follow-up when all other predictors are fixed. bAdjusted for age, gender and time-varying BMI.
Additionally adjusted for metabolic health for CRP, WBC, insulin, LDLC and TC. Adjusted for age, gender and metabolic health for BMI and WHR. cMarkers were natural
log-transformed to achieve an approximately normal distribution. dP>0.05 for the interactions between time and markers and the model did not include the interaction term
due to P>0.05. eAdjusted for age, gender and time-varying BMI. fThe Generalized Estimating Equations model was used to test the effect of transition from impaired fasting
glucose to overt diabetes on metabolically unhealthy over time. The estimate for the effect of transition on metabolically unhealthy represents the change in the OR of
diabetes occurrence corresponding to being metabolically unhealthy compared with being metabolically healthy at any follow-up time, controlling for other predictors. The
estimate for follow-up time on metabolically unhealthy represents if there is a decline/increase over time in the risk for metabolically unhealthy when all other predictors are
fixed. The effect of the factor×follow-up time interaction terms was not significant in models.
Abbreviations: BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure; HDLC, high-density lipoprotein cholesterol; LDLC, low-density lipoprotein
cholesterol; OR, odds ratio; SBP, systolic blood pressure; TC, total cholesterol; TG, triglycerides; WBC, white blood cell; WC, waist circumference; WHR, waist-to-hip.
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older age, women (compared with men) and higher BMI and
concentrations of insulin, fasting glucose, total cholesterol and
DBP significantly contribute to the longitudinal increment of
HbA1c level after adjusting for follow-up time (Table 7).

Discussion
Our data show that the critical factors determining transition
from pre-diabetes to diabetes in a high-risk Mexican-American
cohort are poor metabolic health and increase in BMI. Onethird of our DRS subjects were observed to transition from prediabetes to diabetes during an average period of 27 months (3
months to nearly 11 years), with incidence density of 12.4/100
person-years. Poor metabolic health was the major risk factor, with incidence density of 13.8/100 person-months and an
increased risk of transition to diabetes of 81%. Increasing BMI
over the same time period was also a factor in transition; by
8% for each 1 kg/m2 increase in BMI. These data give strong
indications that the opportunity to impact diabetes is great in

those with pre-diabetes through improving overall metabolic
health and controlling or reducing BMI.
These observations are entirely consistent with our previous study of the association of obesity and metabolic health
with diabetes.25 In that study, highest prevalence of diabetes
was in those obese with significant metabolic abnormalities
and the second highest prevalence in those not obese but with
significant metabolic abnormalities. Although obesity alone
is important, metabolic health is more so.25 Not surprisingly,
diabetes incidence increased over time among subjects with
pre-diabetes. Older age and increased BMI, elevated insulin
levels, HbA1c and triglycerides significantly contribute to the
longitudinal increase in plasma fasting glucose concentrations after adjusting for follow-up time and gender. Similarly,
older age, women (compared with men) and increased BMI,
elevated insulin levels, fasting glucose, total cholesterol and
DBP significantly contribute to the longitudinal increment of
HbA1c levels after adjusting for follow-up time.

Table 6 Estimates for multiple factors associated with the longitudinal change of fasting plasma glucose level after the impaired fasting
glucose diagnosis among 285 Mexican-Americans, 2004–2015, in Cameron County Hispanic Cohort Studya
Multiple factors affecting fasting plasma glucose level (mg/dL) in one model

Estimate (SE)

P-value

Follow-up time (months)
Age (years)
Gender (women versus men)
Body mass index (kg/m2)
Glycated hemoglobin (%)
Insulin (mg/dL)
Triglycerides (mg/dL)

–0.0004 (0.0001)
0.001 (0.0003)
0.0005 (0.009)
0.003 (0.001)
0.008 (0.003)
0.003 (0.0004)
0.0002 (0.00,004)

0.001
<0.0001
0.55
0.0006
0.002
<0.0001
0.0002

Notes: aLinear mixed-effects model was used to test the associations between fasting plasma glucose level (dependent variable) and factors affecting its change for an average
of 9 repeated measures at every 3 to 6 months for an average of 27 months (range: 3–129 months) since baseline. Except age and gender, other factors with significant
univariate effect on glucose level were included in the model. The estimate for the effect of each factor represents the difference in glucose level with 1-unit increase of
each factor (continuous variables) at any follow-up time, controlling for other predictors. The estimate for the effect of gender represents the difference in glucose level
with women versus men at any follow-up time, controlling for other predictors. The estimate for follow-up time represents the rate of glucose level change; the difference
in the glucose level per month of follow-up when all other predictors are fixed. Glucose level was natural log-transformed to achieve an approximately normal distribution.

Table 7 Estimates for multiple factors associated with the longitudinal change of plasma HbA1c level after first observation of transition
to impaired fasting glucose among 285 Mexican-Americans, 2004–2015, in Cameron County Hispanic Cohort Studya
Multiple factors affecting HbA1c (%) level in one model

Estimate (SE)

P-value

Follow-up time (months)
Age (years)
Gender (women versus men)
Body mass index (kg/m2)
Fasting plasma glucose (mg/dL)
Total cholesterol (mg/dL)
Diastolic blood pressure (mmHg)

0.002 (0.0003)
0.002 (0.0006)
0.04 (0.01)
0.003 (0.001)
0.003 (0.0005)
–0.0007 (0.0001)
0.002 (0.0006)

<0.0001
0.0007
0.002
0.02
<0.0001
<0.0001
0.0007

Notes: aLinear mixed-effects model was used to test the associations between plasma HbA1c level (dependent variable) and factors affecting its change for an average of 9
repeated measures at every 3 to 6 months for an average of 27 months (range: 3–129 months) since baseline. Except age and gender, other factors with significant univariate
effect on HbA1c level were included in the model. The estimate for the effect of each factor represents the difference in HbA1c level with 1-unit increase of each factor
(continuous variables) at any follow-up time, controlling for other predictors. The estimate for the effect of gender represents the difference in HbA1c level with women
versus men at any follow-up time, controlling for other predictors. The estimate for follow-up time represents the rate of HbA1c level change; the difference in the HbA1c
level per month of follow-up when all other predictors are fixed. HbA1c level was natural log-transformed to achieve an approximately normal distribution.
Abbreviation: HbA1c, glycated hemoglobin.
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To our knowledge, our study is the first to examine proximal changes accompanying the transition from pre-diabetes
to diabetes among a population of Mexican-Americans with
extreme prevalence of diabetes (27.8%).12 Our findings show
that deteriorating metabolic health and increased BMI are
the most important modifiable risk factors in transition to
diabetes. Although these principles are generally accepted,
they are not widely applied in these high-risk individuals.
Our data emphasize the concept that strategies to improve
metabolic health and maintain or regain normal weight
are key in individuals with pre-diabetes and essential to
controlling the pandemic of diabetes. These concepts are
supported by the literature. A Korean cohort of 406 subjects
with pre-diabetes was followed-up every 3–6 months for up
to 9 years.27 They report a transition rate from pre-diabetes
to diabetes of 20%,27 which was lower than the proportion
of the cases over total number of the subjects (33.7%), but
higher than the rate of 12.5/100 person-years in our study. The
reason for the differences may include ethnicity, population
structure, lifestyles and environment, different definitions
of pre-diabetes and more importantly, different measurement methods. We used incidence density as the measurement of the rate of transition to avoid the effect of different
follow-up periods of time on the rate, or introducing other
bias. That study reported that surrogate markers (30-minute
post-load glucose and C-peptide concentrations) reflecting
β-cell dysfunction were more closely associated with diabetes transition than insulin resistance indices.27 However, all
indices of β-cell dysfunction in that study were calculated
by fasting glucose, which was included in the definition of
diabetes and is, therefore, highly correlated with diabetes,
introducing bias. In support of our findings, several studies
have shown that the metabolic syndrome was a strong predictor of incident diabetes.28–31 However, Asians develop diabetes
at considerably lower BMI than Western populations,32 so it
cannot be assumed that diabetes is a single disease entity but
more likely it is a complex including type 1 diabetes and a
range of maturity-onset diabetes.33 Racial/ethnic disparities
in diabetes prevalence have become most pronounced, and
Mexican-Americans had highest rate compared with other
ethnic groups.34
Our findings extend observations in the literature. Ford35
summarized the findings from 5 major studies that examined
the risk of incident diabetes among subjects with the metabolic syndrome as defined by National Cholesterol Education
Program (NCEP) and the World Health Organization and
reported that random-effects estimate of relative risk was
3.08 (95% CI: 2.16–4.40, P for heterogeneity <0.001). One
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study by Stern et al28 showed that the metabolic syndrome
as defined by the NCEP criteria can predict incident diabetes
in the general population. The Strong Heart Study (SHS),
which is a population-based longitudinal study, showed that
the measures of baseline obesity help predict the transition
to type 2 diabetes in non-diabetic American Indians in the
future, compared with subjects with normal glucose tolerance at baseline.11
Being metabolically unhealthy is a pre-diabetes state and
also a risk factor for the development of type 2 diabetes.36
Impaired insulin secretion with insulin deficiency with or
without insulin resistance is the pathophysiological basis
for the development of type 2 diabetes.36 The underlying
disturbances for the pathophysiology of abnormal triglycerides in type 2 diabetes are hepatic overproduction and delay
clearance of triglyceride-rich lipoproteins the synthesis and
secretion of which is related to insulin resistance.37 Similarly,
the potential mechanism to support that obesity is a predictor
of the transition from pre-diabetes to diabetes may be related
to the reduced insulin sensitivity in adipose tissues among
individuals with impaired fasting glycemia.38 Hyperglycemia in the fasting state seems primarily to be caused by an
inherent insulin secretory dysfunction followed by a decline
in hepatic insulin sensitivity.39 Although not statistically
significant, our findings also show that baseline HOMA-IR
was higher in DRS subjects transitioned from pre-diabetes
to diabetes than those without (3.99 versus 3.71) (Table 1),
while triglycerides were statistically higher in DRS subjects
transitioned from pre-diabetes to diabetes compared with
those without the transition (multivariable-adjusted OR:
1.005; P=0.01) (Table 2). Besides, the etiology involved
in the transition from pre-diabetes to diabetes includes
environmental factors, physical inactivity, diet, smoking
and genetic factors.38 Our study also found that more DRS
subjects who did not transition from pre-diabetes to diabetes
met minimum recommendations for moderate and vigorous
physical activity of ≥600 MET-minutes/week compared
with their counterparts at enrollment (33% versus 16%;
P=0.03) (Table 1). The lack of association was likely because
these factors are not significant determinants of developing
diabetes from pre-diabetes. Alcohol and smoking are not
generally identified as risk factors for diabetes and our study
was no exception. The question of diet is more complex, but
we utilize a standardized method of diet measurement and
none of its components nor the instrument as a whole was
associated with developing diabetes. Overall, the transition
from pre-diabetes states to type 2 diabetes is characterized
by a vicious cycle that includes severe deleterious effects
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on glucose metabolism: reduced hepatic insulin sensitivity,
stationary β-cell dysfunction and/or chronic low β-cell mass,
altered glucagon-like peptide-1 secretion and inappropriately
elevated glucagon secretion.38
There are some limitations in our research. Some measurements, such as physical activity, were self-reported,
which may affect its precision as a predictor. We could not
completely rule out the possibility of residual confounding
due to unmeasured or inadequately measured covariates.
This study had several strengths. First, this wellcharacterized cohort is derived from a general populationbased randomly selected Mexican-American cohort, thus
avoiding bias inherent in studies drawing from clinic
populations or other non-randomly selected populations
with established disease or mixed ethnicity. Second, the
high-intensity, longitudinal study design gives strong power
to explore the predictors related to the transition from prediabetes to diabetes, determine proximal changes accompanying the transition and finally to define a high-risk group
for diabetes prevention. Third, the long-term follow-up
data are very precious as every 3 to 6 months’ follow-up
is time, cost and personnel consuming. Dynamic measures
of glucose regulation also enhanced the prognostic value
for progression to diabetes. Fourth, the transition rate
from pre-diabetes to diabetes in our study was measured
by incidence density or person-time incidence rate. This
measure excludes the effect of how many years each person
contributed to the study when they developed diabetes and
much more accurate than prevalence. To our knowledge,
this is the first study to use incidence density to calculate
the transition rate from pre-diabetes to diabetes. Finally,
we used fasting plasma glucose to diagnose pre-diabetes
in our population-based study due to practicability, cost
and reproducibility compared with other tests. Thus, our
population-based study examined the transition from prediabetes to diabetes in a practical way.
In conclusion, compared with metabolically healthy prediabetes DRS subjects, metabolically unhealthy pre-diabetes
DRS subjects had increased risk of transition to diabetes.
Pre-diabetes DRS subjects with higher BMI were also significantly more likely to convert to diabetes. Being metabolically unhealthy or having higher BMI level accompanied the
transition. Being metabolically unhealthy and higher BMI
are modifiable harmful factors amenable to modification and
reduction of risk in Mexican-Americans. Efforts should be
primarily focused on improving metabolic health and weight
control intervention.
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• Deteriorating metabolic health and/or increasing
body mass index (BMI) significantly raises the risk
of transitioning from pre-diabetes to diabetes among
Mexican-Americans with pre-diabetes.
• Transition itself was accompanied by further increase in
BMI and deterioration in metabolic health.
• These data underline the importance of improving metabolic health and avoiding weight gain in pre-diabetes as
simple but clear diabetes prevention targets and emphasize the importance of lifestyle management.
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